Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PTGX

Protagonist Therapeutics Inc

Feb 26 • 01:30PM ET

35.53

Dollar change +0.44
Percentage change 1.25	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR VTI IWM CALF XBI VXF AVUV IJT IWO SPSM

Scroll to Statements

Index	RUT	P/E	8.45	EPS (ttm)	4.21	Insider Own	5.85%	Shs Outstand	61.04M	Perf Week	-7.79%
Market Cap	2.18B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-7.32%	Shs Float	57.79M	Perf Month	-7.38%
Income	275.19M	PEG	-	EPS next Q	-0.03	Inst Own	100.53%	Short Float	6.56%	Perf Quarter	-14.69%
Sales	434.43M	P/S	5.02	EPS this Y	-133.00%	Inst Trans	3.29%	Short Ratio	6.14	Perf Half Y	-14.76%
Book/sh	11.06	P/B	3.21	EPS next Y	23.30%	ROA	49.81%	Short Interest	3.79M	Perf Year	24.75%
Cash/sh	6.82	P/C	5.21	EPS next 5Y	-	ROE	54.39%	52W Range	24.22 - 48.89	Perf YTD	-7.95%
Dividend Est.	-	P/FCF	11.93	EPS past 5Y	-	ROI	40.14%	52W High	-27.33%	Beta	2.34
Dividend TTM	-	Quick Ratio	12.48	Sales past 5Y	2607.12%	Gross Margin	99.32%	52W Low	46.70%	ATR (14)	1.69
Dividend Ex-Date	-	Current Ratio	12.48	EPS Y/Y TTM	405.40%	Oper. Margin	58.20%	RSI (14)	39.48	Volatility	5.59% 4.25%
Employees	126	Debt/Eq	0.02	Sales Y/Y TTM	624.05%	Profit Margin	63.34%	Recom	1.18	Target Price	58.73
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	348.29%	Payout	0.00%	Rel Volume	0.80	Prev Close	35.09
Sales Surprise	28.92%	EPS Surprise	42.60%	Sales Q/Q	184.40%	Earnings	Feb 21 BMO	Avg Volume	618.05K	Price	35.53
SMA20	-5.87%	SMA50	-7.25%	SMA200	-9.74%	Trades		Volume	312,364	Change	1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23

Show Previous Ratings

Feb-21-25 08:35AM	Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:34AM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-12-25 07:51AM	Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
06:15PM	Loading…
Jan-29-25 06:15PM	Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025 (ACCESSWIRE)
Jan-06-25 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Dec-19-24 04:05PM	Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 (ACCESSWIRE)
Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
05:30PM	Loading…
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
08:20AM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-01-24 08:00AM	RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
07:00AM	Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
09:15AM	Loading…
Jul-31-24 09:15AM	Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor (ACCESSWIRE)
Jul-22-24 07:00AM	Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 (ACCESSWIRE)
Jul-18-24 08:50AM	Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-11-24 06:00AM	3 Growth Stocks No One Is Watching (But They Should Be) (InvestorPlace)
Jun-28-24 04:07PM	Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 (Investor's Business Daily) +8.69%
12:11PM	Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024 (Associated Press)
Jun-27-24 05:44PM	Protagonist Therapeutics Set to Join S&P SmallCap 600 (PR Newswire)
01:43PM	Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy? (Insider Monkey)
Jun-26-24 10:12PM	10 Best Healthcare Stocks to Buy Under $50 (Insider Monkey)
Jun-14-24 03:00AM	Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control (ACCESSWIRE)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace) +16.10%
May-31-24 07:30AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 (ACCESSWIRE)
May-14-24 04:05PM	Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress (ACCESSWIRE) +6.28%
May-07-24 11:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.12%
09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)
04:23PM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event (ACCESSWIRE)
04:05PM	Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +8.05%
04:05PM	Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
09:05AM	Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting (ACCESSWIRE)
Nov-01-23 04:05PM	Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis (ACCESSWIRE)
07:30AM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Oct-30-23 04:05PM	Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors (ACCESSWIRE)
Oct-09-23 07:00AM	Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications (ACCESSWIRE)
Oct-03-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Sep-05-23 07:30AM	Protagonist Therapeutics to Present at Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Aug-09-23 07:00AM	Protagonist Receives $34 Million from Warrant Exercises (ACCESSWIRE)
Aug-03-23 04:48PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-18-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Jul-05-23 09:33AM	Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment (Benzinga)
Jul-04-23 03:30AM	Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis (ACCESSWIRE)
Jun-30-23 08:50AM	Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-15-23 09:55AM	Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know (Zacks)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATEL DINESH V PH D	President and CEO	Feb 19 '25	Sale	38.18	5,359	204,607	540,260	Feb 20 05:25 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Option Exercise	8.04	26,000	209,040	62,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Option Exercise	8.04	5,529	44,453	51,973	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Sale	44.70	26,000	1,162,280	46,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Sale	45.60	5,529	252,122	46,444	Nov 27 07:11 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Option Exercise	7.75	175,000	1,356,000	359,611	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Option Exercise	12.17	30,450	370,576	286,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Sale	46.04	103,437	4,762,239	256,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Sale	45.50	19,191	873,190	266,983	Nov 27 07:09 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Option Exercise	21.58	1,727	37,269	429,935	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Sale	46.96	78,520	3,687,299	435,208	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 26 '24	Sale	46.25	21,480	993,450	408,455	Nov 27 07:08 PM
MOLINA ARTURO MD	Officer	Nov 27 '24	Proposed Sale	44.00	16,000	704,000		Nov 27 04:39 PM
MOLINA ARTURO MD	Officer	Nov 26 '24	Proposed Sale	45.00	16,000	720,000		Nov 26 07:39 PM
Gupta Suneel	Officer	Nov 26 '24	Proposed Sale	45.50	19,191	873,184		Nov 26 07:37 PM
Gupta Suneel	Officer	Nov 25 '24	Proposed Sale	46.46	103,437	4,805,683		Nov 25 05:40 PM
Dinesh Patel	CEO	Nov 25 '24	Proposed Sale	45.93	100,000	4,593,000		Nov 25 04:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '24	Sale	40.98	1,906	78,108	46,444	Nov 19 06:49 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Option Exercise	15.68	12,000	188,160	46,960	Sep 13 04:35 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Sale	44.49	14,203	631,872	34,960	Sep 13 04:35 PM
Waddill William D.	Director	Sep 10 '24	Option Exercise	12.88	8,000	103,040	20,000	Sep 12 07:38 PM
Waddill William D.	Director	Sep 10 '24	Sale	45.00	8,000	360,000	12,000	Sep 12 07:38 PM
Ali Asif	Officer	Sep 11 '24	Proposed Sale	44.49	14,203	631,855		Sep 11 06:15 PM
WILLIAM D WADDILL	Director	Sep 10 '24	Proposed Sale	45.00	8,000	360,000		Sep 10 04:17 PM
Waddill William D.	Director	Jul 24 '24	Option Exercise	12.88	8,000	103,040	20,000	Jul 26 04:31 PM
Waddill William D.	Director	Jul 24 '24	Sale	40.00	8,000	320,000	12,000	Jul 26 04:31 PM
Waddill William D.	Director	Jun 07 '24	Option Exercise	12.88	8,000	103,040	20,000	Jun 11 04:30 PM
Waddill William D.	Director	Jun 07 '24	Sale	35.00	8,000	280,000	12,000	Jun 11 04:30 PM
PATEL DINESH V PH D	President and CEO	Jun 07 '24	Sale	35.19	35,000	1,231,650	515,415	Jun 11 04:30 PM
Ali Asif	Chief Financial Officer	Apr 18 '24	Sale	25.11	1,234	30,986	37,163	Apr 19 08:05 PM
PATEL DINESH V PH D	President and CEO	Apr 01 '24	Sale	28.31	25,000	707,750	549,590	Apr 02 08:29 PM
SELICK HAROLD E	Director	Mar 07 '24	Option Exercise	1.89	6,490	12,266	27,996	Mar 11 08:00 PM
PATEL DINESH V PH D	President and CEO	Mar 01 '24	Sale	31.62	30,000	948,600	574,590	Mar 01 08:46 PM
Waddill William D.	Director	Mar 01 '24	Option Exercise	6.09	12,975	79,018	24,975	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Sale	31.34	12,975	406,636	12,000	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Option Exercise	12.17	12,000	146,040	52,645	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Sale	32.24	14,248	459,318	38,397	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Feb 29 '24	Sale	30.69	9,939	305,048	40,645	Mar 01 08:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience